The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing share buy-back program. As of April 1, 2025, the company has repurchased a total of 2,072,302 ordinary fully paid securities, with 98,349 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: -11.59%
Average Trading Volume: 747
Technical Sentiment Signal: Buy
Current Market Cap: $996.7M
For an in-depth examination of NEU stock, go to TipRanks’ Stock Analysis page.